Marburgviruses: An Update

Caterina M. Miraglia, DC, MLS(ASCP)


Lab Med. 2019;50(1):16-28. 

In This Article

Treatment and Vaccines

Treatment for MVD is supportive.[62] Medical record keeping and clinical data collection have been insufficient in MVD outbreaks; therefore, data regarding the effectiveness of supportive treatments are lacking.[44] Currently, no United States Food and Drug Administration (FDA)–approved treatment or vaccine is available that specifically targets filoviruses.[62]

Due to the devastating effects and high number of casualties caused by the Angola MVD outbreak in 2005 and the Ebola epidemic from 2014 through 2016,[1,2] it is imperative that effective treatment and vaccines are developed. Researchers have evaluated promising compounds in vitro and in animal studies with different mechanisms of action, including reduction in viremia and inflammation, inhibition of viral attachment, budding, entry into the cytoplasm, replication, and monoclonal antibodies targeting various viral components, with varying efficacies. These compounds possibly could be useful for prophylaxis or treatment of MVD (Table 3).[63–83] Potential vaccine candidates have been developed and evaluated in animal and human studies, using various platforms, involving recombinant viruses expressing GP or VPs of MARV and/or RAVV, and DNA-vectored vaccines (Table 4).[84–92] Many of the treatment and vaccine studies also incorporated the ebolaviruses.